Friday 24th May 2019
Boehringer Ingelheim publish new data on experimental ILD drug
Approximately 25% of people who live with systemic sclerosis (SSc) also develop significant pulmonary (lung) involvement within 3 years of diagnosis. Nintedanib could make a considerable difference to the lives of people with this rare and often life-threatening disease.